论文部分内容阅读
RU486是法国Roussel Uclaf公司合成的一种孕酮受体水平拮抗剂,临床实践证明该化合物具有较好的催经止孕效果。为进一步明确RU486的作用机理,本文测定了早孕妇女服用RU486后蜕膜组织孕、雌激素受体含量及血清激素水平。结果表明,一次口服RU486 600mg可使早孕5—7周妇女蜕膜组织细胞核内孕、雌激素受体含量增加,细胞浆内孕激素受体含量减少,血清雌二醇(E_2)、睾酮(T)含量上升而对FSH、HCG和孕酮(P)含量无明显影响。本研究结果进一步证实,大剂量的抗孕激素RU486能竞争性地结合蜕膜组织孕激素受体,使早孕期高浓度的内源性孕酮与其受体的正常结合受到干扰,从而达到抗早孕目的。
RU486 is a kind of antagonist of progesterone receptor synthesized by Roussel Uclaf in France. It has been proved by clinical practice that RU486 has better effect of promoting menstruation and stopping pregnancy. In order to further clarify the mechanism of action of RU486, this study determined the pregnancy, estrogen receptor levels and serum hormone levels in decidual tissue of RU pregnant women after taking RU486. The results showed that oral administration of RU486 600 mg for 1 to 5 weeks in pregnant women could increase the levels of estrogen receptor and progesterone receptor in the decidual tissue of pregnant women, ) Content increased with no significant effect on the contents of FSH, HCG and progesterone (P). The results of this study further confirmed that RU486, a high-dose anti-progestogen, competitively binds to progesterone receptors in decidual tissues and interferes with the normal binding of high concentrations of endogenous progesterone to its receptors in early pregnancy, thus achieving anti-early pregnancy purpose.